CYT387, a selective JAK1/JAK2 inhibitor: In vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

Medicine & Life Sciences

• N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 100%
• Janus Kinase 2 72%
• Janus Kinase Inhibitors 72%
• Polycythemia Vera 66%
• Phosphotransferases 39%
• Inhibitory Concentration 50 38%
• Cell Line 30%
• In Vitro Techniques 22%
• Leukemia, Erythroblastic, Acute 22%
• Alleles 18%
• STAT5 Transcription Factor 12%
• K562 Cells 10%
• Erythropoietin 9%
• Transducers 8%
• Growth 8%
• Adenosine Triphosphate 6%
• Phosphorylation 5%
• Neoplasms 5%
• Mutation 4%
• Therapeutics 1%